Intervention

F/TAF

ClinicalTrials.gov intervention label

Clinical trials9

Recruiting0

Common conditions6

Lead sponsors shown1

Clinical trials

9 shown

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionNCT04994509 · 2021-08-30

ACTIVE_NOT_RECRUITING

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVNCT04143594 · 2019-11-22

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically SuppressedNCT03110380 · 2017-06-12

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsNCT02607956 · 2015-11-11

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TCNCT02469246 · 2015-06-29

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsNCT02397694 · 2015-03-23

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing RegimenNCT02285114 · 2015-01-20

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDFNCT02121795 · 2014-05-06

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVNCT02016924 · 2014-01-16

ACTIVE_NOT_RECRUITING

Common conditions

HIV-1 Infection4 HIV-1-infection2 Acquired Immune Deficiency Syndrome (AIDS)1 HIV Infections1 HIV-11 Pre-Exposure Prophylaxis of HIV Infection1

Leading sponsors

Gilead Sciences9

Trial status mix

COMPLETED7

ACTIVE_NOT_RECRUITING2

Phase mix

PHASE37

PHASE24

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.